Coloplast Current Valuation vs. EBITDA
| COLO-B Stock | DKK 889.40 2.40 0.27% |
For Coloplast profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Coloplast to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Coloplast AS utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Coloplast's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Coloplast AS over time as well as its relative position and ranking within its peers.
Coloplast |
Coloplast AS EBITDA vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Coloplast's current stock value. Our valuation model uses many indicators to compare Coloplast value to that of its competitors to determine the firm's financial worth. Coloplast AS is the top company in current valuation category among its peers. It also is number one stock in ebitda category among its peers totaling about 0.04 of EBITDA per Current Valuation. The ratio of Current Valuation to EBITDA for Coloplast AS is roughly 28.15 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Coloplast by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Coloplast's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Coloplast Current Valuation vs. Competition
Coloplast AS is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Medical Instruments & Supplies industry is currently estimated at about 535.02 Billion. Coloplast totals roughly 203.46 Billion in current valuation claiming about 38% of all equities under Medical Instruments & Supplies industry.
Coloplast EBITDA vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Coloplast |
| = | 203.46 B |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Coloplast |
| = | 7.23 B |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Coloplast EBITDA Comparison
Coloplast is currently under evaluation in ebitda category among its peers.
Coloplast Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Coloplast, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Coloplast will eventually generate negative long term returns. The profitability progress is the general direction of Coloplast's change in net profit over the period of time. It can combine multiple indicators of Coloplast, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Coloplast AS develops and markets intimate healthcare products and services worldwide. Coloplast AS was founded in 1954 and is headquartered in Humlebk, Denmark. Coloplast operates under Healthcare Products classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 12000 people.
Coloplast Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Coloplast. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Coloplast position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Coloplast's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Coloplast without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
| All Next | Launch Module |
Use Investing Themes to Complement your Coloplast position
In addition to having Coloplast in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Mid Cap ETFs Thematic Idea Now
Mid Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Mid Cap ETFs theme has 70 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Mid Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Coloplast Stock
To fully project Coloplast's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Coloplast AS at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Coloplast's income statement, its balance sheet, and the statement of cash flows.